Merck & Co. Stock Rises by 4.84%, Driven by Prospects of an End to the US Shutdown

Merck & Co. Closes at $90.95, Up 4.84%

Merck & Co. closed at $90.95 on Tuesday, marking a significant appreciation of 4.84% compared to the previous session. The trading volume reached over 15.3 million shares, representing 0.62% of the market capitalization traded on the day. This capital turnover reflects a definite interest from operators in the stock, though not considered exceptionally intense by historical standards of the stock. Tuesday's performance contrasts sharply with the annual performance of the stock. Since November 11, 2024, Merck has indeed declined by 9.71%. This twelve-month decline contrasts with the dynamics displayed by its benchmark index, the Dow Jones, which recorded an appreciation of 11.30% over the same period. Merck's weekly gain of 8.45% suggests a recent dynamic of improvement, indicating a catch-up movement after several months of underperformance. Merck benefits from a solid relative valuation compared to its peers in the health sector. The market capitalization to earnings ratio stands at 11.4 times earnings, significantly below the sector average of 17.8 times. This gap raises a catch-up potential evaluated by analysts at 29.5% according to their price targets. The strength of the group is based on a diversified pharmaceutical portfolio and well-established animal health activities, forming a defensive foundation in the current economic environment.

Merck's Progress on Tuesday Part of a Broader US Market Movement

Merck's progress on Tuesday is part of a broader movement in the US markets, fueled by concrete advancements towards lifting the government shutdown. For fifty-three days, the federal government has been partially closed, disrupting administrative activities and creating significant macroeconomic uncertainty. On Tuesday, events accelerated towards a potential resolution of this prolonged administrative crisis. The House of Representatives, returning to Washington after this exceptional break, is preparing to vote on a transitional budget project, already approved by the Senate. Only two steps remain to end the crisis: adoption by the House and presidential signature. Market forecasting platforms anticipate a resolution as early as this week, reflecting increased confidence from operators about an imminent conclusion. This dynamic has triggered a reallocation of portfolios and a new appetite for defensive and cyclical stocks. The health sector, of which Merck is an undeniable leader, traditionally benefits from resilient demand during phases of macroeconomic uncertainty. Conversely, technology stocks related to artificial intelligence faced setbacks on Tuesday, fueled by concerns over high valuations and significant selling of positions by institutional investors. This redistribution of flows partly explains the outperformance observed in the pharmaceutical sector giants. The gradual easing of internal US uncertainty thus creates conditions for a normalization of exchanges and a restoration of the investment climate.